There is currently great excitement among clinicians and scientists in the field of personalized treatment of cancer. Today’s advances in the biology of cancer and development of new tools for genome analysis have provided for a fresh perspective in what is commonly known today as personalized medicine. This type of medicine is centered on the tumor. The concept is not new and previous attempts to customize treatment have been carried out by the patient himself. Despite its limitations, decades ago body surface area based dosing was already a first step in this promising treatment type. Today, application of new pharmacokinetics (PK) and pharmacogenetics-driven concepts still provide some of the most promising tools for improving treatment management and clinical outcomes in patients with cancer.
Transgenomic is a global biotechnology company pushing the envelope on personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and research services. The company is the global leader in cardiac genetic testing with several products, including its flagship C-GAAP test. The test is designed to detect gene mutations which indicate cardiac disorders, or which can lead to adverse problems down the road. Transgenomic has three divisions. They are Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, a producer of equipment, reagents, and other consumables that aid clinical and research applications in molecular testing and cytogenetics. Transgenomic sees great opportunity for further growth in all three businesses by using their synergistic capabilities, technologies, and expertise.
TBIO’s management team is built for success. Sandra J. Gunselman Ph. D. and Vice President of Clinical Operations achieved a B.S. in Biology from the David Lipscomb University and a Ph.D. in Cellular & Molecular Biology from Colorado State University. Dr. Gunselman has two decades of molecular biology lab experience. Dr. Gunselman specializes in DNA damage and repair.
For more information on the company, visit www.transgenomic.com
Let us hear your thoughts below:
